NCT05572671 Linking Brain Network Dynamics to Imminent Smoking Lapse Risk and Behavior
| NCT ID | NCT05572671 |
| Status | Recruiting |
| Phase | — |
| Sponsor | Penn State University |
| Condition | Smoking |
| Study Type | INTERVENTIONAL |
| Enrollment | 150 participants |
| Start Date | 2023-04-04 |
| Primary Completion | 2027-07 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
You will actively receive the study intervention — which may be a drug, biologic, device, or procedure.
This trial targets 150 participants in total. It began in 2023-04-04 with a primary completion date of 2027-07.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
Most attempts to quit smoking end in relapse, or a return to regular smoking. One of the biggest threats to cessation is a lapse (i.e., any cigarette use during a quit attempt). Thus, characterizing why lapses occur is essential to understanding and preventing smoking relapse. Functional magnetic resonance imaging (fMRI) is a promising method for characterizing the psychological processes that lead to smoking lapses because it provides a way to measures patterns of brain activity thought to reflect relevant mental processes as they change over time. However, methodological issues have hindered the ability to capitalize on this potential and prevented an understanding of how brain activity and corresponding psychological processes unfold in the critical moments that immediately precede a smoking lapse. The proposed project will address this knowledge gap using a novel fMRI paradigm adapted from a well-validated behavioral lapse task. The goals of the project are to characterize changes in brain activity that lead up to a lapse and to investigate how these changes are related to concurrent affect and subsequent cigarette use.
Eligibility Criteria
Inclusion Criteria: * Participants must be between the ages of 21 and 65. * Participants must be fluent English speakers. * Participants must pass an MRI safety screening. * Participants must report smoking at least six cigarettes per day continuously for at least the 12 preceding months. * Participants must have a baseline expired-air carbon monoxide exceeding 10 parts per million in order to verify smoking status. Exclusion Criteria: * Individuals will be excluded if they report that they are not willing to refrain from using nicotine for 12 hours before the experimental lab visit. * Individuals will be excluded if they have any known risk from exposure to high-field strength magnetic fields (e.g., pacemakers), any irremovable metallic foreign objects in their body (e.g., braces), or a questionable history of metallic fragments that are likely to create artifact on the MRI scans.
Frequently Asked Questions
Who can join the NCT05572671 clinical trial?
This trial is open to participants of all sexes, aged 21 Years or older, up to 65 Years, studying Smoking. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
Is NCT05572671 currently recruiting?
Yes, NCT05572671 is actively recruiting participants. Visit ClinicalTrials.gov or contact Penn State University to inquire about joining.
Where is the NCT05572671 trial being conducted?
This trial is being conducted at University Park, United States.
Who is sponsoring the NCT05572671 clinical trial?
NCT05572671 is sponsored by Penn State University. The trial plans to enroll 150 participants.